Glen L. Hortin
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Glen L. Hortin has a total of 117 co-authors. Here are the top co-authors by number of shared publications:
Denis Sviridov
Department of Laboratory Medicine, Clinical Center, National Institutes of Health, Bethesda, MD
4 shared publicationsAlan T. Remaley
3 shared publicationsBonnie Meilinger
Departments of Laboratory Medicine and Critical Care Medicine, Warren Magnuson Clinical Center, National Institutes of Health, Bethesda, MD
2 shared publicationsGerard T. Hoehn
Departments of Laboratory Medicine and Critical Care Medicine, Warren Magnuson Clinical Center, National Institutes of Health, Bethesda, MD
2 shared publicationsSteven K. Drake
Departments of Laboratory Medicine and Critical Care Medicine, Warren Magnuson Clinical Center, National Institutes of Health, Bethesda, MD
2 shared publicationsAaron D. Bossler
1 shared publication
Latest Publications
- 1 January 2012
- Published by Elsevier
Contributors
- Open Access
- 1 October 2008
- Published by Oxford University Press (OUP) in Clinical Chemistry
- Vol. 54 (10) , 1608-1616
High-Abundance Polypeptides of the Human Plasma Proteome Comprising the Top 4 Logs of Polypeptide Abundance
Background: Plasma contains thousands of proteins, but a small number of these proteins comprise the majority of protein molecules and mass.Content: We surveyed proteomic studies to identify candidates for high-abundance polypeptide chains. We searched the literature for information on the plasma concentrations of the most abundant components in healthy adults and for the molecular mass of the mature polypeptide chains in plasma. Because proteomic studies usually dissociate proteins into polypeptide chains or detect short peptide segments of proteins, we summarized data on individual peptide chains for proteins containing multiple subunits or polypeptides. We collected data on about 150 of the most abundant polypeptides in plasma. The abundant polypeptides span approximately the top 4 logs of concentration in plasma, from 650 to 0.06 μmol/L on a molar basis or from about 50 000 to 1 mg/L mass abundance.Conclusions: Data on the concentrations of the high-abundance peptide chains in plasma assist in understanding the composition of plasma and potential approaches for clinical laboratory or proteomic analysis of plasma proteins. Development of more extensive databases regarding the plasma concentrations of proteins in health and diseases would promote diagnostic and proteomic advances.
- 1 October 2008
- Published by Oxford University Press (OUP) in Clinical Chemistry
- Vol. 54 (10) , 1608-1616
Open AccessHigh-Abundance Polypeptides of the Human Plasma Proteome Comprising the Top 4 Logs of Polypeptide Abundance
Background: Plasma contains thousands of proteins, but a small number of these proteins comprise the majority of protein molecules and mass.Content: We surveyed proteomic studies to identify candidates for high-abundance polypeptide chains. We searched the literature for information on the plasma concentrations of the most abundant components in healthy adults and for the molecular mass of the mature polypeptide chains in plasma. Because proteomic studies usually dissociate proteins into polypeptide chains or detect short peptide segments of proteins, we summarized data on individual peptide chains for proteins containing multiple subunits or polypeptides. We collected data on about 150 of the most abundant polypeptides in plasma. The abundant polypeptides span approximately the top 4 logs of concentration in plasma, from 650 to 0.06 μmol/L on a molar basis or from about 50 000 to 1 mg/L mass abundance.Conclusions: Data on the concentrations of the high-abundance peptide chains in plasma assist in understanding the composition of plasma and potential approaches for clinical laboratory or proteomic analysis of plasma proteins. Development of more extensive databases regarding the plasma concentrations of proteins in health and diseases would promote diagnostic and proteomic advances.
- 21 July 2008
- Published by Wiley in Proteomics – Clinical Applications
- Vol. 2 (7-8) , 950-955
Analysis of molecular forms of albumin in urine
Albumin is not only one of the most abundant urinary protein components and one of the most widely used clinical markers for kidney disease, it also is a significant source of molecular complexity of the urinary proteome and peptidome. Urine contains multiple fragments and modified forms of albumin. Analysis of molecular forms of albumin in urine is of fundamental importance for understanding clinical assays for albumin quantification, specimen stability, and proteomic and peptidomic analysis of urine.
- 21 July 2008
- Published by Wiley in Proteomics – Clinical Applications
- Vol. 2 (7-8) , 950-955
Analysis of molecular forms of albumin in urine
Albumin is not only one of the most abundant urinary protein components and one of the most widely used clinical markers for kidney disease, it also is a significant source of molecular complexity of the urinary proteome and peptidome. Urine contains multiple fragments and modified forms of albumin. Analysis of molecular forms of albumin in urine is of fundamental importance for understanding clinical assays for albumin quantification, specimen stability, and proteomic and peptidomic analysis of urine.
- Open Access
- 1 April 2007
- Published by Oxford University Press (OUP) in Clinical Chemistry
- Vol. 53 (4) , 543-544
A New Era in Protein Quantification in Clinical Laboratories: Application of Liquid Chromatography-Tandem Mass Spectrometry
- 1 April 2007
- Published by Oxford University Press (OUP) in Clinical Chemistry
- Vol. 53 (4) , 543-544
Open AccessA New Era in Protein Quantification in Clinical Laboratories: Application of Liquid Chromatography-Tandem Mass Spectrometry
- 27 February 2007
- Published by Taylor & Francis in Pharmacogenomics
- Vol. 8 (3) , 237-255
Diagnostic Potential for Urinary Proteomics
Urine represents a modified ultrafiltrate of plasma, with protein concentrations typically approximately 1000-fold lower than plasma. Urine's low protein concentration might suggest it to be a less promising diagnostic specimen than plasma. However, urine can be obtained noninvasively and tests of many urinary proteins are well-established in clinical practice. Proteomic technologies expand opportunities to analyze urinary proteins, identifying more than 1000 proteins and peptides in urine. Urine offers a sampling of most plasma proteins, with increased proportions of low-molecular-weight protein and peptide components. Urine also offers enriched sampling of proteins released along the urinary tract. Although urine presents some challenges as a diagnostic specimen, its diverse range of potential markers offers great potential for diagnosis of both systemic and kidney diseases. Examples of clinical situations where this may be of value are for more sensitive detection of kidney transplant rejection or of renal toxicity of medications.
- 27 February 2007
- Published by Taylor & Francis in Pharmacogenomics
- Vol. 8 (3) , 237-255
Diagnostic Potential for Urinary Proteomics
Urine represents a modified ultrafiltrate of plasma, with protein concentrations typically approximately 1000-fold lower than plasma. Urine's low protein concentration might suggest it to be a less promising diagnostic specimen than plasma. However, urine can be obtained noninvasively and tests of many urinary proteins are well-established in clinical practice. Proteomic technologies expand opportunities to analyze urinary proteins, identifying more than 1000 proteins and peptides in urine. Urine offers a sampling of most plasma proteins, with increased proportions of low-molecular-weight protein and peptide components. Urine also offers enriched sampling of proteins released along the urinary tract. Although urine presents some challenges as a diagnostic specimen, its diverse range of potential markers offers great potential for diagnosis of both systemic and kidney diseases. Examples of clinical situations where this may be of value are for more sensitive detection of kidney transplant rejection or of renal toxicity of medications.
- 1 December 2006
- Published by Oxford University Press (OUP) in Clinical Chemistry
- Vol. 52 (12) , 2258-2264
Bound Homocysteine, Cysteine, and Cysteinylglycine Distribution between Albumin and Globulins
Background: Major portions of homocysteine (Hcy), cysteine (Cys), cysteinylglycine (CysGly), and glutathione in serum are covalently bound to proteins via disulfides. Albumin has been considered the dominant binding protein.
- 1 December 2006
- Published by Oxford University Press (OUP) in Clinical Chemistry
- Vol. 52 (12) , 2258-2264
Bound Homocysteine, Cysteine, and Cysteinylglycine Distribution between Albumin and Globulins
Background: Major portions of homocysteine (Hcy), cysteine (Cys), cysteinylglycine (CysGly), and glutathione in serum are covalently bound to proteins via disulfides. Albumin has been considered the dominant binding protein.
- 1 July 2006
- Published by Oxford University Press (OUP) in Clinical Chemistry
- Vol. 52 (7) , 1223-1237
The MALDI-TOF Mass Spectrometric View of the Plasma Proteome and Peptidome
Background: Matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS) and the related technique, surface-enhanced laser desorption/ionization (SELDI)-TOF MS, are being applied widely to analyze serum or plasma specimens for potential disease markers.
- 1 July 2006
- Published by Oxford University Press (OUP) in Clinical Chemistry
- Vol. 52 (7) , 1223-1237
The MALDI-TOF Mass Spectrometric View of the Plasma Proteome and Peptidome
Background: Matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS) and the related technique, surface-enhanced laser desorption/ionization (SELDI)-TOF MS, are being applied widely to analyze serum or plasma specimens for potential disease markers.
- Open Access
- 1 July 2006
- Published by Oxford University Press (OUP) in Clinical Chemistry
- Vol. 52 (7) , 1218-1222
Proteomics: A New Diagnostic Frontier
Background: Analysis of proteins has been an integral part of the field of clinical chemistry for decades. Recent advances in technology and complete identification of the human genome sequence have opened up new opportunities for analysis of proteins for clinical diagnostic purposes.
- 1 July 2006
- Published by Oxford University Press (OUP) in Clinical Chemistry
- Vol. 52 (7) , 1218-1222
Open AccessProteomics: A New Diagnostic Frontier
Background: Analysis of proteins has been an integral part of the field of clinical chemistry for decades. Recent advances in technology and complete identification of the human genome sequence have opened up new opportunities for analysis of proteins for clinical diagnostic purposes.
- 10 March 2006
- Published by American Society for Microbiology
- p. 4-6
Introduction to Protein Analysis
- Open Access
- 1 March 2006
- Published by Oxford University Press (OUP) in Clinical Chemistry
- Vol. 52 (3) , 389-397
Coelution of Other Proteins with Albumin during Size-Exclusion HPLC: Implications for Analysis of Urinary Albumin
Background: Size-exclusion HPLC has been used as an alternative to immunoassays for quantifying urinary albumin (microalbumin). Systematically higher values for the HPLC method have been proposed to result from nonimmunoreactive albumin.
- 1 March 2006
- Published by Oxford University Press (OUP) in Clinical Chemistry
- Vol. 52 (3) , 389-397
Open AccessCoelution of Other Proteins with Albumin during Size-Exclusion HPLC: Implications for Analysis of Urinary Albumin
Background: Size-exclusion HPLC has been used as an alternative to immunoassays for quantifying urinary albumin (microalbumin). Systematically higher values for the HPLC method have been proposed to result from nonimmunoreactive albumin.